Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 7/20 | 0.67 |
| ▸ | NT5C2 | P49902 | 2/20 | 0.58 |
| ▸ | NT5E | P21589 | 1/20 | 0.56 |
| ▸ | STAT3 | P40763 | 3/20 | 0.54 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8121393 | 0.86 | STAT3 (0.69) | BRD4NT5C2NT5ESTAT3CREBBP | |
| SCHEMBL475842 | 0.85 | BRD4 (0.66) | BRD4NT5C2NT5ESTAT3CREBBP | |
| SCHEMBL5694204 | 0.85 | BRD4 (0.66) | BRD4NT5C2NT5ESTAT3CREBBP | |
| SCHEMBL8446397 | 0.84 | BRD4 (0.64) | BRD4NT5C2NT5ESTAT3CREBBP | |
| SCHEMBL10432005 | 0.82 | BRD4 (0.62) | BRD4NT5C2NT5ESTAT3CREBBP | |
| SCHEMBL23124 | 0.81 | BRD4 (1.00) | BRD4NT5C2NT5ECREBBPBTK | |
| SCHEMBL29514799 | 0.81 | BRD4 (1.00) | BRD4NT5C2NT5ECREBBPBTK | |
| SCHEMBL8381776 | 0.80 | BRD4 (0.97) | BRD4NT5C2NT5ECREBBPBTK | |
| SCHEMBL5694112 | 0.79 | NPC1 (0.49) | — | |
| SCHEMBL5694222 | 0.79 | GDA (0.55) | BRD4BTKTNNI3K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1645561-A1 | METHOD OF SYNTHESIZING CYCLIC BISDINUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2006-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | NSUN2, POLR2H, POLB | BRD4 434/4885NT5C2 710/4885NT5E 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.